Interstitial lung disease with progressive fibrotic phenotype in diseases classified elsewhere
ICD-10 J84.170 is a billable code used to indicate a diagnosis of interstitial lung disease with progressive fibrotic phenotype in diseases classified elsewhere.
Interstitial lung disease with progressive fibrotic phenotype in diseases classified elsewhere refers to a group of lung disorders characterized by inflammation and scarring (fibrosis) of the lung tissue. This condition often arises as a complication of other diseases, such as autoimmune disorders, infections, or environmental exposures. Clinically, patients may present with progressive dyspnea (shortness of breath), a persistent dry cough, and decreased exercise tolerance. The anatomy involved primarily includes the alveoli and interstitial spaces of the lungs, where the fibrotic changes occur, leading to impaired gas exchange. Disease progression can vary, with some patients experiencing rapid deterioration while others may have a more indolent course. Diagnostic considerations include high-resolution computed tomography (HRCT) scans, pulmonary function tests, and sometimes lung biopsies to confirm the presence of fibrosis and rule out other conditions. Early recognition and management are crucial to slow disease progression and improve quality of life.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
J84.170 encompasses interstitial lung diseases that exhibit a progressive fibrotic phenotype due to underlying conditions such as systemic sclerosis, rheumatoid arthritis, or sarcoidosis. The diagnosis is often confirmed through imaging and clinical evaluation.
J84.170 should be used when the interstitial lung disease is secondary to another classified condition and exhibits a progressive fibrotic phenotype. It is important to differentiate it from primary interstitial lung diseases, which have specific codes.
Documentation should include a clear diagnosis of the underlying condition, imaging studies showing fibrotic changes, pulmonary function test results, and any relevant clinical notes that indicate the progressive nature of the lung disease.
